Clinician Use of Clover Assistant is Associated with Significant Improvement in the Early Identification and Management of Chronic Kidney Disease
01 Agosto 2023 - 5:20PM
Today, Clover Health (“Clover” or “the Company”) issued an analysis
titled Clover Assistant Use and Diagnosis and Progression of
Chronic Kidney Disease, which examines the association between use
of the company’s flagship technology product, Clover Assistant
(“CA”), and earlier physician identification and management of
stage three chronic kidney disease (“CKD”).
“Our findings demonstrate that use of Clover Assistant supports
earlier diagnosis and management of chronic disease,” said Dr.
Kumar Dharmarajan, Chief Medical Officer of Clover Assistant.
“Importantly, we’re seeing that when doctors use Clover Assistant,
not only is CKD diagnosed earlier in its progression, but the rate
of kidney decline decelerates. While chronic deterioration of
kidney function cannot be reversed, any deceleration delays CKD
complications like heart attacks and strokes, and reduces health
costs. We’re using technology in a scalable way to positively
influence physician behavior and improve lives.”
“To reduce any potential for bias, the analysis leverages data
from the same physician cohort before and after their adoption of
Clover Assistant. By removing this variable, we can confidently
ascertain that the disease identification models within Clover
Assistant are catalysts for improved disease management,” added
Peter Loscutoff, Data Science Fellow at Clover.
“Clover Assistant helps me manage my patients’ CKD earlier. I
find that when using it with my Clover patients, I am ordering
CKD-related tests like parathyroid hormone (PTH) sooner, which then
allows me to manage the condition and its complications earlier,”
said Dr. Amr Kahf of The Armor Medical Group, in Haledon, New
Jersey.
The full results are available on Clover’s website:
www.cloverhealth.com/clinicalcare/ckd
About Clover Health:Clover Health (Nasdaq:
CLOV) is a physician enablement company committed to bringing
access to great healthcare to everyone on Medicare. This includes a
health equity-based focus on seniors who have historically lacked
access to affordable, high-quality healthcare. Our strategy is
powered by our software platform, Clover Assistant, which is
designed to aggregate patient data from across the healthcare
ecosystem to support clinical decision-making and improve health
outcomes through the early identification and management of chronic
disease. We operate two distinct lines of business: Insurance and
Non-Insurance. Through our Insurance line of business, we provide
PPO and HMO Medicare Advantage plans in several states, with a
differentiated focus on our flagship wide-network, high-choice PPO
plans. Our Non-Insurance line of business similarly aims to reduce
cost-of-care while enhancing the quality of care for patients
enrolled in Original Medicare.
Press Contact:Andrew
Still-Baxterpress@cloverhealth.com
Investor Relations Contact:Ryan
Schmidtinvestors@cloverhealth.com
Clover Health Investments (NASDAQ:CLOV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Clover Health Investments (NASDAQ:CLOV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024